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Introduction. Acute kidney injury (AKI) necessitating continuous renal replacement therapy (CRRT) is a severe complication in
trauma patients (TP). We wanted to assess daily duration of CRRT and its impact on uremic control in TP. Material and Methods.
We retrospectively reviewed adult TP, with or without rhabdomyolysis, with AKI undergoing CRRT. Data on daily CRRT duration
and causes for temporary stops were collected from the ﬁrst ﬁve CRRT days. Uremic control was assessed by daily changes in
serum urea (Δurea) and creatinine (Δcreatinine) concentrations. Results. Thirty-six TP were included with a total of 150 CRRT
days, 17 (43%) with rhabdomyolysis. The median (interquartile range (IQR)) time per day with CRRT was 19 (15–21) hours.
There was a signiﬁcant correlation between daily CRRT duration and Δurea (r = 0.60, P ≤ 0.001) and Δcreatinine (r = 0.43;
P = 0.012). CRRT pauses were caused by ﬁlter clotting (54%), therapeutic interventions (25%), catheter related problems (10%),
ﬁlter timeout (6%), and diagnostic procedures (6%). Rhabdomyolysis did not aﬀect the CRRT data. Conclusions. TP undergoing
CRRT had short daily CRRT duration causing reduced uremic control. Clinicians should modify their daily clinical practice to
improve technical skills and achieve suﬃcient dialysis dose.
1.Introduction
Acute kidney injury (AKI) is a serious complication among
intensive care unit (ICU) patients associated with increased
morbidity and mortality [1, 2]. Dialysis is utilized in the
most severe cases to control ﬂuid overload and ensure
solute removal [3]. Hemodialysis can be administered either
intermittently (IHD) or continuously (CRRT). CRRT is the
preferred modality in the ICU because it has a similar
mortality [4, 5], but enhanced hemodynamic stability com-





not known, and several studies on mixed ICU patients show
conﬂicting results on how dialysis dose inﬂuences dialysis
dependency, morbidity, and mortality [10, 11]. Finally, since
pauses and interruptions during low-eﬃcacy dialysis such
as CRRT may adversely aﬀect uremic control [12, 13],
the diﬀerence between prescribed and actually performed
d i a l y s i sd o s ed e s e r v e sm o r ea t t e n t i o n[ 12–14]. Uchino et
al. showed in a prospective study that temporary stops
accounted for 20% of the potential operative time of CRRT,
and made the authors suggest that “down-time” from CRRT
could serve as a quality indicator, since it was closely related
to solute removal [13].
Trauma is a major disease among young people leading
to increased disability and mortality [15]. Tissue injury
with release of toxic substances and complications such as
bleeding and infection might predispose patients to develop
organ failures. Kidney function can also be aﬀected; in severe
cases CRRT is necessary and contributes to a considerable
rise in consumption of healthcare resources [7]. However, in2 Critical Care Research and Practice
a large multicenter study of AKI in the ICU, trauma patients
accounted for only 2% of the patients [16]. Rhabdomyolysis,
wherestriatedmusclenecrosisleadstoreleaseofintracellular
muscularconstituentssuchascreatinekinaseandmyoglobin
into the circulation, contributes to development of AKI [17,
18]. Such muscular necrosis might cause kidney toxicity in
trauma patients and act together with other prerenal, renal,
and postrenal causes of AKI in the ICU [19].
Although clinical data on dialysis therapy is available
for mixed ICU populations, data are lacking for the small
subgroup of trauma patients. In a recent retrospective study
of trauma patients admitted to our surgical ICU, we found
an incidence rate of AKI requiring CRRT close to 8%, with
a one-year mortality rate of 40% [19]. However, in patients
receiving CRRT, we did not report the “down-time,” or
possible adverse eﬀects on uremic control. Thus, the aims
of this retrospective study were to assess daily duration
of CRRT, reasons for temporary stops, and the impact of
daily CRRT duration on uremic control in trauma patients
with and without rhabdomyolysis admitted to a surgical
ICU. Our hypothesis was that trauma patients had several
temporary stops during CRRT due to frequent diagnostic
procedures and therapeutic interventions causing reduced
uremic control.
2.MaterialandMethods
2.1. Study Population. Oslo University Hospital is the re-
gional trauma referral centre for approximately 2.5 million
people in Norway, whereof 1.93 million adults (>18 years).
A retrospective evaluation of all adult trauma patients who
developed AKI treated with CRRT between January 1, 1997,
and December 31, 2006, was performed. Persons with either
chronic renal failure or CRRT lasting less than 24 hours were
excluded from further analysis. The study was reviewed and
approved by The Norwegian Data Inspectorate and Regional
Committee for Medical Research Ethics.
2.2.DataCollection. Traumaadmissions included alltrauma
diagnosis codes except late eﬀects, foreign bodies and
complications. Diagnosis codes for acute renal failure were
used to identify patients with AKI, and procedure codes for
continuous dialysis to ﬁnd patients undergoing CRRT. Infor-
mation was sought from hospital charts, medical records,
institutional trauma, and intensive care registries as well as
the national renal registry. Detailed data on daily CRRT
duration for each patient was obtained from separate CRRT
observational charts. Blood samples at 6 am from the ﬁrst
ﬁ v ed a y so fC R R Tw e r ec o l l e c t e d .
2.3. Study Deﬁnitions. The deﬁnition of trauma admissions,
AKI, and CRRT were as described above and previously
presented in detail [19]. Simpliﬁed acute physiology score
II (SAPS II) [20] was used to assess severity of illness, and
the injury severity score (ISS) [21] to assess severity of
trauma. Patients were group according to the presence of
rhabdomyolysis, which was deﬁned as peak serum creatine
kinase above 10.000U/L (the trigger for initiation of forced
alkaline diuresis at our hospital during the study period).
The general indications for dialysis were classiﬁed at
initiation of CRRT as the follows:
(i) ﬂuid overload (leading to an oxygenation problem);
(ii) hyperkalemia (serum potassium > 5.0mmol/L);
(iii) acidosis (whole blood pH < 7.25);
(iv) uremia (serum urea > 30mmol/L);
(v) rhabdomyolysis (serum creatine kinase > 10.000
U/L).
CRRT pauses were classiﬁed based on the primary cause of
the pause as being either:
(i) ﬁlter clotting (dialysis ﬁlter pressure primarily in-
creased);
(ii) catheter-related (access and/or return pressure pri-
marily decreased/increased);
(iii) diagnostic procedure (resulting in discontinuation of
the CRRT circuit);
(iv) therapeutic intervention (resulting in discontinua-
tion of the CRRT circuit);
(v) ﬁlter timeout (preplanned regular change of ﬁlter
every 72 hours of CRRT).
Uremic control was assessed by calculating daily percent
changes in serum urea and creatinine levels, that is, as Δurea
and Δcreatinine. Δurea = (ureadayN −ureaday N + 1)/ureadayN,
where ureadayN is the serum concentration of urea at
day N, and ureadayN+1 is the serum concentration of
urea at day N + 1. Δcreatinine = (creatininedayN −
creatininedayN+1)/creatininedayN, where creatininedayN is the
serum concentration of creatinine at day N, and
creatininedayN+1 is the serum concentration of creatinine
at day N + 1. A value of Δurea or Δcreatinine equal to 0
indicated that the serum levels of urea and creatinine did not
change from one day to the next; a positive value indicated
a decrease, and a negative value an increase in serum
concentration. Median values for Δurea and Δcreatinine
from the ﬁrst ﬁve days of CRRT were calculated for each
individual and were used to assess day-to-day stability in
uremic control.
2.4. Strategy for Renal Replacement Therapy. The attending
intensive care physician prescribed CRRT, while the ICU
nurses carried out the treatment. Indication for initiation
CRRT was individualized and was frequently consisting of
combinations of low urine output, severe hypervolemia,
metabolic acidosis, and increased serum concentrations of
urea, creatinine, and/or potassium. During the ten years, we
used diﬀerent dual lumen, straight dialysis catheters with
length 15–20 centimeters, diameter 11.5–12 French, either
Mahurkar (Covidien, MA, USA) or GamCath (Gambro,
Lund, Sweden). The dialysis catheters were inserted in
the internal jugular, subclavian or femoral vein depend-
ing on availability. One CRRT modality was used duringCritical Care Research and Practice 3
thestudy period, thatis, continuous venovenous hemodiaﬁl-
tration (CVVHDF) using Prisma (Gambro, Lund, Sweden)
machines. The dialysis doses were individualized based on
body weight and clinical judgment without a speciﬁed pro-
tocol. Typically settings were blood ﬂow 80–120mL/minute,
dialysate ﬂow: 750–1250mL/hour and replacement ﬂow:
750–1250mL/hour. Settings were adjusted to maintain an
ultraﬁltration rate of 9–14%. Only biocompatible synthetic
dialysis membranes were used. Post-dilution mode was the
preferred routine, unless recurrent ﬁlter clotting indicated
the use of the pre-dilution mode. Lactate-buﬀered solutions
were used during the ﬁrst years, with a gradual change to
bicarbonate-buﬀered ﬂuids currently used. Anticoagulation
was often delayed due to increased bleeding tendency, but
was otherwise achieved using systemic heparin with target
activated prothrombin time (APTT) of 50–70 seconds.
Switch to IHD was done in some patients when the he-
modynamic situation was stabilized.
2.5. Statistical Analyses. Statistical analysis was performed
with the statistical package for social sciences (SPSS) for
Windows, version 15.0 (SPSS Inc., Chicago, IL, USA).
Data are presented for the total population with the sub-
groups with or without rhabdomyolysis. Categorical data
are expressed as number and percent, and compared using
Pearson chi-square test, proportions are reported with 95%
conﬁdence interval (CI). Continuous data are presented
as median and interquartile range (IQR; 25th to 75th
percentiles), and compared using Mann-Whitney U test.
Linear regression analysis was conducted to assess a possible
association between the daily CRRT duration and uremic
control, and evaluate the property of correlation. The level of
statistical signiﬁcance was set at P<0.05. Based on multiple
measurements in each patient, we calculated median values
for daily CRRT duration, Δurea, and Δcreatinine for each
individual. This was to ensure that calculated P values were
not invalidated by dependent data set.
3. Results
3.1. Baseline Patient Data. A total of 40 trauma patients were
treated with CRRT during the study period. Four patients
were excluded from the analysis due to either known chronic
renal failure (n = 3) or CRRT lasting less than 24 hours
(n = 1).Thus,36patientswithatotalof150CRRTdayswere
included and further analyzed (Figure 1). Data on median
Δurea, and median Δcreatinine are missing for three patients
as their CRRT lasted only one day and was terminated before
blood samples were drawn at 6 am. Baseline demographics,
kidney function, CRRT indications, and performance data
as well as outcome are presented in Table 1. The included
patients were preferably young males with severe injuries
based on their ISS- and SAPS II-scores (Table 1).
3.2. CRRT Performance Data. Individual data on CRRT
performance and uremic control is presented in Table 2.
The median daily duration of CRRT was 19 (IQR 15–21)
hours (Table 1; Figures 2 and 3), or 78% of the possible
operative time. There was a total of 126 temporary stops
during CRRT caused by ﬁlter clotting 68 (54%, 95% CI 45–
63%), therapeutic interventions 32 (25%, 95% CI 17–33%),
catheter-related problems 12 (10%, 95% CI 5–15%), ﬁlter
timeout 7 (6%, 95% CI 2–10%), and diagnostic procedures
7 (6%, 95% CI 2–10%).
3.3. Uremic Control during CRRT. Serum concentrations of
urea increased during CRRT with median 5.0% per day,
whereas serum levels of creatinine decreased with median
5.0% per day. Linear regression analysis showed a signiﬁcant
correlation between median daily CRRT duration and Δurea
as well as Δcreatinine. For all patients the median Δurea =
−9.36 + 0.49 x median daily CRRT duration, r = 0.60,
P<0.001. Median Δcreatinine = −5.28 + 0.37 x median
daily CRRT duration, r = 0.43, P = 0.012. With the dialysis
dose achieved in these patients, 19.1 and 14.3 hours of CRRT
per day were required in order to maintain stable serum
concentrations of urea and creatinine, respectively (Figures
2 and 3).
3.4. Rhabdomyolysis. Seventeen (43%) of the patients were
classiﬁed as having rhabdomyolysis and were compared to
the 19 patients without rhabdomyolysis (Tables 1 and 2
and Figures 2 and 3). Reasons for pauses were more often
therapeutic interventions in the rhabdomyolysis group (38%
versus12%,resp.,P<0.01),andﬁltertimeoutinthepatients
without rhabdomyolysis (2% versus 10%, resp., P = 0.04).
However, no diﬀerence between the two groups was found
in median daily CRRT duration (16.3 versus 19.7 hours per
day, resp., P = 0.19), median Δurea (−0.06 versus −0.05,
resp., P = 0.20), or median Δcreatinine (0.03 versus 0.12,
resp., P = 0.21). When comparing patients with and without
rhabdomyolysis, no diﬀerence in the correlation between
median daily CRRT duration and median Δurea (P = 0.71),





possible time), whereas time on CRRT in other ICU patients
in previous studies has varied between 19 and 23 hours per
day [11, 13, 14].
For several reasons trauma patients with AKI might be
diﬀerent from other ICU patients thereby requiring adjust-
ments of their dialysis therapy. First, trauma patients often
have large primary and secondary muscular damage causing
rhabdomyolysis and rise in metabolic waste products. Sec-
ondly, anticoagulation is challenging since trauma patients
often have increased bleeding risk. Finally, as documented
in the present study, trauma patients are frequently absent
from the ICU due to diagnostic procedures and therapeutic
interventions remote from the ICU. However, our study
shows that there is a potential for improvement, since
almost 2/3 of the CRRT interruptions were due to technical
diﬃculties; either ﬁlter clotting or catheter-related problems.4 Critical Care Research and Practice




Trauma patients with continuous
renal replacement therapy
Included







(n = 17) (n = 19)
Excluded
- Chronic renal failure (n = 3)
- Dead within 24 hours (n = 1)
Figure 1: Flow chart of 36 adult trauma patients treated with continuous renal replacement therapy for acute kidney injury grouped with
and without rhabdomyolysis.
The actually performed CRRT in this study was insuf-
ﬁcient in order to reduce serum urea concentrations, but
did at least reduce creatinine levels. Above nineteen hours of
CRRT per day was required to maintain stable urea levels,
and only around 14 hours per day to preserve creatinine
concentrations. In contrast, 16 hours of CRRT per day
were needed to maintain serum concentrations of both urea
and creatinine in a previous study of mixed ICU patients
[14]. We might speculate that this diﬀerence in dialysis
time for maintaining urea and creatinine concentrations in
trauma patients could be explained by extensive muscular
damage either due to the primary trauma [22] or secondary
catabolism [23], which may cause increased production of
protein degradation products such as urea.
Filter clotting (74–78%) was the main reason for in-
terruptions of CRRT in previous studies of mixed ICU
patients [13, 14]. Our present data on trauma patients
indicates that this ﬁlter clotting was responsible for a little
more than half of these interruptions. In trauma patients,
however, systemic anticoagulation is often restricted due
to fair of extensive bleeding, especially in the critical early
phase after admission. Some recent data suggest that ﬁlter
clotting might be counteracted by more use of regional
anticoagulation during CRRT [24]. Since ﬁlter clotting
impact negatively on achieved dialysis dose, it deserves more
attention both for trauma patients and mixed ICU patients
and warrants clinical studies. Moreover, there is always
potential for improvements of technical skills among the
clinicians, as catheter-related problems accounted for 10% of
the interruptions. Issues such as equipment used, insertion
techniques, insertion place, daily routines and hygiene must
beacontinuousfocusintheICUanddeservesmoreresearch.
Diagnostic procedures and therapeutic interventions
were in the present study responsible for 31% of the
temporary stops during CRRT, while in previous reports
of general ICU patients this has occurred more seldom
[13, 14]. Trauma patients often have injuries in several
organ systems requiring repetitive and longlasting diagnostic
procedures and therapeutic interventions such as gastroin-
testinal, thoracic, orthopedic or brain surgery [25], and/or
angiographic embolization [26–28]. This may aﬀect the
initial phase of CRRT, as patients often are absent from
the ICU during stabilization. A possible handling of this
problem might be use of IHD or intraoperative CRRT
during prolonged operations, which has been proven to be
achievable and safe during other surgical interventions such
as liver transplantations [29].
Dialysis dosing is a highly relevant clinical issue [30]
that during low-eﬃcacy dialysis such as CRRT is dependent
not only on the prescribed dialysis doses, but also on the
operative time. As CRRT performance data are lacking in
trauma patients, this study contributes to new knowledge
regarding daily duration of CRRT, reasons for temporary
stops and impact of CRRT duration on uremic control in
posttraumatic AKI. The clinical implication of our study
is that measures should be taken to avoid interruptions
during CRRT in trauma patients. This could possibly be
achieved by increased use of regional anticoagulation and/or
intraoperative use of CRRT. An alternative is to use IHD or
increase the prescribed dialysis doses per hour during CRRT
in order to achieve adequate solute removal. In our clinical
practice, we have now implemented educational programs
forCRRTrunbydedicatedICUnurses.Wehaverecentlyalso
developed a CRRT protocol with standardized indications
for CRRT, weight adjusted dialysis doses (approximately
30mL/kg/hour), and criteria for discontinuation of CRRT.
In addition, we have changed anticoagulation from systemic
heparin to regional citrate.Critical Care Research and Practice 5
Table 1: Patient characteristics: Trauma patients with acute kidney injury with continuous renal replacement therapy (CRRT) grouped with
and without rhabdomyolysis (n = 36).







Age (years) 48 (30–65) 35 (23–51) 57 (44–68) 0.01
Male gender 31 (86) 17 (100) 14 (74) 0.02
SAPS II score 41 (32–48) 38 (31–48) 41 (32–49) 0.90
ISS score 34 (26–47) 43 (17–50) 34 (27–41) 0.24
Indication for CRRT
Fluid overload 19 (53) 8 (47) 11 (58) 0.52
Hyperkalemia 20 (56) 9 (53) 11 (58) 0.77
Acidosis 15 (42) 3 (18) 12 (63) 0.01
Uremia 9 (25) 4 (24) 5 (26) 0.85
Rhabdomyolysis 17 (47) 17 (100) 0 (0) <0.01
Kidney function at start of CRRT
Diuresis (mL/day) 536 (256–1692) 522 (252–2060) 550 (255–1410) 0.80
Serum potassium (mmol/L) 5.0 (4.2–5.5) 4.4 (4.0–5.7) 5.1 (4.8–5.5) 0.20
Serum urea (mmol/L) 17.8 (12.5–28.4) 13.6 (10.6–25.0) 22.2 (16.3–29.8) 0.07
Serum creatinine (µmol/L) 249 (204–376) 247 (198–483) 269 (215–361) 0.95
Serum creatine kinase (U/L) 4638 (460–24414) 24415 (9660–45740) 603 (135–2152) <0.01
CRRT performance data







Median Δcreatinine 0.05 (−0.04–0.17) 0.03 (−0.17–0.15) 0.12 (0.01–0.17) 0.21
Filter clotting pauses 68 (54) 36 (55) 32 (53) 0.90
Therapeutic pauses 32 (25) 25 (38) 7 (12) <0.01
Catheter-related pauses 12 (10) 3 (5) 9 (15) 0.05
Filter timeout pauses 7 (6) 1 (2) 6 (10) 0.04
Diagnostic pauses 7 (6) 5 (8) 2 (3) 0.30
Outcome
Dialysis-dependent 3 months 0 (0) 0 (0) 0 (0) n.c.
Dialysis-dependent 1 year 0 (0) 0 (0) 0 (0) n.c.
Mortality 3 months 11 (31) 3 (18) 8 (42) 0.11
Mortality 1 year 13 (36) 4 (24) 9 (47) 0.14
Categorical data are presented as number (percent) and compared using Pearson chi-square test. Continuous data are expressed as median (interquartile
range) and are compared using 2-tailed Mann-Whitney U test. SAPS II: simpliﬁed acute physiology score II. ISS: injury severity score. n.c.: not calculated. See
text for other deﬁnitions.
In the subgroup analysis of patients with and without
rhabdomyolysis we revealed that median daily CRRT dura-
tion and markers for uremic control were similar in the two
groups. However, there were more pauses due to therapeutic
interventions in the rhabdomyolysis group compared to
patients without rhabdomyolysis, as can be expected due to
increased need of surgical procedures in this group.
The main limitation of this study is the small number
of patients included, as well as the retrospective and obser-
vational design. Uremic control is inﬂuenced by a number
of factors not accounted for in the present study, such as
ﬁlter properties, modality of CRRT, gender, body weight,
nutritionalsupportandothers[31].Itstillremainsuncertain
whether uremic control aﬀects prognosis in general ICU
patients and trauma patients. However, uremic control is
strongly related to the dialysis dose, but these data were
unfortunately not collected and would have added valuable
information. Additionally, serum concentrations of urea and
creatinine are probably only surrogate markers of uremia,
as the relationship between blood levels and toxicity in
humans is still under debate [32]. Further, we realize
that the present results may not be applicable to other6 Critical Care Research and Practice
Table 2: Individual data: Trauma patients with acute kidney injury with continuous renal replacement therapy (CRRT) grouped with and
without rhabdomyolysis (n = 36).
Patient number Rhabdomyolysis CRRT
days
Median daily
CRRT duration Median Δurea Median
Δcreatinine
1 No 5 21,1 −0,05 −0,05
2 No 5 19,7 0,10 0,22
3 No 5 22,3 0,15 0,15
4 No 5 22,3 0,12 0,17
5 Yes 5 16,8 0,03 0,14
6 Yes 5 20,8 0,01 0,01
7 No 3 18,7 −0,10 0,16
8 Yes 5 22,8 0,03 0,04
9 No 5 18,7 0,11 0,28
10 No 5 21,8 −0,08 0,02
11 Yes 5 19,2 0,23 0,25
12 No 4 16,1 −0,01 0,13
13 Yes 1 9,1
14 No 5 23,8 −0,14 0,01
15 Yes 4 16,1 0,17 0,18
16 No 5 9,8 −0,23 −0,12
17 Yes 5 10,3 −0,18 −0,02
18 No 5 21,4 0,08 0,03
19 Yes 4 18,5 −0,14 −0,18
20 Yes 4 15,8 −0,02 0,21
21 Yes 1 24,0
22 No 2 15,6 −0,06 0,05
23 Yes 5 16,3 −0,20 −0,24
24 No 5 23,5 0,17 0,25
25 Yes 5 18,5 −0,10 −0,05
26 No 4 11,5 −0,08 −0,15
27 Yes 2 16,1 0,03 0,08
28 No 5 14,4 −0,09 −0,03
29 No 5 19,4 0,04 0,01
30 No 4 14,6 −0,07 0,18
31 Yes 5 13,0 −0,30 −0,32
32 Yes 1 24,0
33 No 5 19,9 0,18 0,12
34 Yes 3 11,8 −0,35 0,05
35 No 5 20,9 −0,07 0,12
36 Yes 3 8,6 −0,19 −0,17
Δurea = (UreadayN−UreadayN+1)/UreadayN where UreadayN is the serum concentration of urea at day N, and Urea dayN+1 is the serum concentration of urea at
day N+1.
Δcreatinine=(CreatininedayN−CreatininedayN+1)/CreatininedayN whereCreatininedayN istheserumconcentrationofcreatinineatdayN,andCreatininedayN+1
is the serum concentration of creatinine at day N+1.
hospitals due to wide variations in the practical performance
of CRRT [33–35]a n dap o s s i b l ed i ﬀerent deﬁnition of
rhabdomyolysis [17, 18]. The analysis of the two subgroups
withandwithoutrhabdomyolysis shouldbeinterpreted with
caution,astherearerelativelyfewpatientsineachgroupwith
limited statistical power (type II error). Finally, the results of
this study cannot be directly compared to former studies of
temporary stops during CRRT, since we reported the CRRT
duration during the ﬁrst ﬁve days of CRRT, whereas others
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Figure 2: Scattergram of median daily CRRT duration and median Δurea in the total population and the subgroups with and without
rhabdomyolysis. Linear regression analysis showed a signiﬁcant relationship between median daily CRRT duration and median Δurea in the
whole group, r = 0.60, P<0.001.




























Figure 3: Scattergram of median daily CRRT duration and median Δcreatinine in the total population and the subgroups with and without
rhabdomyolysis. Linear regression analysis showed a signiﬁcant relationship between median daily CRRT duration and median Δcreatinine
in the whole group, r = 0.43, P = 0.012.
diﬀerent dialysis dose [13, 14]. This study is also stricter in
statistical analysis than former studies, since we calculated
median values for each person while others calculated data
severaltimesfromthesameindividual[13,14].Despitethese
shortcomings, the present retrospective study may serve as
a basis for future clinical prospective studies of CRRT and
dialysis dosing in trauma patients.
5. Conclusions
Trauma patients undergoing CRRT had relatively short daily
CRRT duration causing reduced uremic control. Most of
the pauses during CRRT were due to technical diﬃculties
suchasﬁlterclotting orcatheter-relatedproblems.Clinicians
should therefore not only modify their daily clinical practice8 Critical Care Research and Practice
in order to improve their technical skills and achieve a
suﬃcient dialysis dose, but also keep a continuous focus
on quality improvement during CRRT. Future prospective
clinical studies of CRRT in trauma patients are needed.
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